title: Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.
abstract: Post-transplantation bronchiolitis obliterans syndrome (BOS) is a clinicopathological syndrome characterised histologically by obliterative bronchiolitis (OB) and physiologically by airflow limitation. It affects long-term survival with no consistently effective treatment strategy.An updated review of risk factors for OB/BOS, and approaches to prevention and treatment was performed through a systematic review of relevant studies between January 1990 and February 2005. The initial search identified 853 publications, with 56 articles reviewed after exclusions. Early acute rejection is the most significant risk factor, with late rejection (> or =3 months) also significant. Lymphocytic bronchitis/bronchiolitis is relevant, with later onset associated with greater risk. Viral infections are identified as significant risk factors. Human leukocyte antigen matching and OB/BOS development is a weaker association, but is stronger with acute rejection. Recipient and donor characteristics have a minor role. There is limited evidence that altering immunosuppression is effective in reducing the rate of decline in lung function. BOS reflects an allo-immunological injury, possibly triggered by cytomegalovirus and respiratory viral infections, or noninfectious injury. Immunological susceptibility may be reflected by more frequent acute rejection episodes. Preventative and therapeutic modifications in immunosuppression remain important. Identifying markers of immunological susceptibility and, hence, risk stratification requires further research.
authors.affiliation: Transplant Unit, Papworth Hospital NHS Trust, Papworth Everard, Cambridge, UK.
authors.forename: Andrew I R
authors.initials: AI
authors.lastname: Scott
authors.forename: Linda D
authors.initials: LD
authors.lastname: Sharples
authors.forename: Susan
authors.initials: S
authors.lastname: Stewart
mesh_terms: D001989:Bronchiolitis Obliterans / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D004198:Disease Susceptibility; D006801:Humans; D012307:Risk Factors; D013577:Syndrome